Pfizer reports Celebrex heart risk

Share this article:
Pfizer reported Friday that a study has found an increased risk of heart problems in patients taking its pain medication Celebrex.
The increased heart risk was found in one of two long-term cancer studies. A second study showed no increased heart risk.
The National Cancer Institute, which conducted the study for Pfizer, halted the use of Celebrex after finding patients taking 400mg to 800mg of the drug daily had a risk of encountering heart problems 2.5 times greater than those not taking the drug.
Celebrex is in the same COX-2 class of pain drugs as Merck's Vioxx, which was pulled from the market in September. A separate study found that patients taking Vioxx were at risk of encountering heart problems at a rate of three times greater than those not taking the drug.
Earlier this month, the FDA said it would be adding a warning label to another Pfizer COX-2 drug, Bextra, after finding an increased heart risk in patients taking the drug who had recent heart bypass surgery.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.